Entry Point Capital, LLC Cytokinetics Inc Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Entry Point Capital, LLC holds 10,923 shares of CYTK stock, worth $484,981. This represents 0.23% of its overall portfolio holdings.
Number of Shares
10,923
Previous 8,825
23.77%
Holding current value
$484,981
Previous $465,000
10.32%
% of portfolio
0.23%
Previous 0.27%
Shares
3 transactions
Others Institutions Holding CYTK
# of Institutions
397Shares Held
122MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$651 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$529 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$477 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.89MShares$350 Million0.07% of portfolio
-
State Street Corp Boston, MA6.17MShares$274 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.18B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...